Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. - Wikidata - awgldk - TriplyDB

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

http://www.wikidata.org/entity/Q53787362

about

Galeterone for the treatment of advanced prostate cancer: the evidence to date Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Detection fidelity of AR mutations in plasma derived cell-free DNA Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.Liquid biopsy: ready to guide therapy in advanced prostate cancer?The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.The molecular underpinnings of prostate cancer: impacts on management and pathology practice.New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.Emerging Variants of Castration-Resistant Prostate Cancer.Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer.Clinical relevance of androgen receptor alterations in prostate cancer.Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation.The evolution of chemotherapy for the treatment of prostate cancer.Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer.Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature.A Prospective Genome-Wide Study of Prostate Cancer Metastases Reveals Association of Wnt Pathway Activation and Increased Cell Cycle Proliferation with Primary Resistance to Abiraterone Acetate-Prednisone.Non-invasive actionable biomarkers for metastatic prostate cancer.Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).Prostate cancer in 2016: Improved outcomes and precision medicine come within reach.Liquid biopsies and plasma DNA: paving the way for personalized medicine in metastatic castration-resistant prostate cancer.Androgen action in prostate function and disease.Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.Genetics and biology of prostate cancer Frequent mutation of the untranslated region in prostate cancer The Clinical Genomics of Prostate Cancer Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer Plasma androgen receptor and serum chromogranin A in advanced prostate cancer

P2860

Q26739887-42BC64C1-3D47-41F3-BDF8-2F4EBA8C99E8 Q36398998-66BB3390-7C95-45CE-AED9-1961383E69F4 Q37716596-CAC15D23-2306-4355-86FA-7BD1EED1F568 Q38375252-E2723E68-35B4-43D2-AA12-33FBBD6420E1 Q38644658-EDCDD9D5-150A-4269-A6CC-F2832434FC98 Q38756919-429B6105-4E79-452D-9E53-FAE5CD1CAACE Q38804089-466A0DBD-FEB5-434D-9868-9B206CB9275B Q38815964-FF98958C-29FF-4D67-AF71-68AC1DE3A773 Q38840458-4CC49E0A-9CDF-4682-B5A4-534C2DD51614 Q38982680-A9A878B1-86F6-4126-8C2C-B84AE71ECE2D Q38983790-573C79CC-5DA1-40C7-963A-EE797A4450BA Q38994718-DFD9F40F-0CBE-4F0C-9124-95F5686E056E Q39210257-31AE1834-24F1-4F2D-A2B2-C249EC41041B Q39454057-2C8A2B50-DA30-4432-B3D2-BFBF5D08709C Q39484267-AF6D902F-AF97-4F3F-8731-F4DD791F4F39 Q40423383-534D8326-C41A-45F3-B7A4-735081EFE1E7 Q40496979-B970D480-D53D-4DE2-AB80-CABB5C5C82A7 Q42370326-3502C76A-5468-4D53-BBBB-A6CA77F84A9F Q42377108-751C43D9-B100-4DE9-915C-7380E96BA17C Q42390872-7D51BFCF-71D5-426B-9984-46DCE471BF69 Q45943517-180D5997-5A6C-470C-9797-7A768403BD35 Q46007270-3C210F4B-0227-4DC8-B27F-737B059C5676 Q46086455-A8D13542-1E96-4C98-9109-BAFBAB9C0991 Q47281377-E76444E8-7A83-48F8-BF1A-EA7857F11715 Q47563363-ABED1508-C75F-4CD2-8E46-375D4249E617 Q49242804-6979DE8B-205D-4B5C-9D39-5980FBEB7C34 Q49913687-67D34B9C-89D3-46CC-B9BE-577B37A19E89 Q50082541-4A6E919A-D52D-4FD0-A284-38C28DEFC209 Q51789456-1A8495DB-A679-4946-AEB3-6743DA650B46 Q52637922-4A4DD4D8-A424-411C-8576-4308FB20AB2E Q52676556-2B87E956-36D9-48F9-AA7C-BC78CA5DAA7B Q53595905-0198C3A1-5480-4778-A183-4D3058C2A851 Q53741855-5A8F10E0-6993-47A4-8B79-5036CB75746C Q55251761-00308E67-374B-48BC-9BD1-4D6323DF6137 Q55343494-9CBF41DE-3F4F-4AC3-B994-C2DADA90B33D Q57106917-549F8F5B-98FB-4BD6-8BEB-19854F9665CB Q57132120-F032A62C-7F44-4CCC-9108-B5C83FF72BB6 Q57288339-2F74F9C0-3299-415A-B2D3-C60FFD4023EB Q57492447-7EFE28BC-A47F-46A4-854A-1A6F80641A52 Q58603582-0D858791-735A-47EA-9537-DE40BC983696

P2860

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

http://www.wikidata.org/entity/Q53787362

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Genomic Alterations in Cell-Fr ...... ion-Resistant Prostate Cancer.

@en

Genomic Alterations in Cell-Fr ...... ion-Resistant Prostate Cancer.

@nl

type

label

Genomic Alterations in Cell-Fr ...... ion-Resistant Prostate Cancer.

@en

Genomic Alterations in Cell-Fr ...... ion-Resistant Prostate Cancer.

@nl

prefLabel

Genomic Alterations in Cell-Fr ...... ion-Resistant Prostate Cancer.

@en

Genomic Alterations in Cell-Fr ...... ion-Resistant Prostate Cancer.

@nl

P1433

Q53787362-2CE68CD2-B37D-4681-A1D2-F03AF5C09550

P1476

Q53787362-6BB526B1-9F36-4879-8D52-2A81135A7A91

P2093

Q53787362-1104576B-82A7-4C27-B384-77232870FC48

Q53787362-1D7A4460-0681-497A-970C-0BF0E477B0CC

Q53787362-2200BCCF-8F9E-4612-BA67-C5F2C55799CD

Q53787362-31311C80-FCA6-4FE5-904C-2AC1127F0457

Q53787362-4A4433EC-607D-4FC3-BD7B-11F4886FB249

Q53787362-4EECA36F-CB50-4BAE-8A95-95CE3A4BB4FE

Q53787362-6C0E3A90-4823-473B-AF44-CBFD89C5CD26

Q53787362-857039B0-D468-498B-82B5-3DE15F1BE293

Q53787362-8940CBF2-B902-455C-8D60-43CE31D36651

Q53787362-A3DC148A-8BE7-49C8-AE2E-AF90BCD0F1A6

P2860

Q53787362-058EDBD5-EDF9-40F5-AB6C-A5B7FA0C595B

Q53787362-11972879-576C-4A5F-9ECD-05A4887E80E9

Q53787362-1511072B-83B5-4E74-B3F5-1223B4355FEB

Q53787362-1D8C349E-4C2F-4DB4-AB58-C2311868D7B1

Q53787362-23743BDE-B017-47AB-9CA0-52E25BDCD378

Q53787362-238E3778-4AF2-4198-B54B-5D18A221E37D

Q53787362-23E5238B-1A90-43E0-BFAA-06200011A517

Q53787362-26565331-6D9E-426E-A86B-98E43207042F

Q53787362-28B9435A-28E5-47E7-BEBE-EEE04EE3FC3A

Q53787362-2DEEAD9E-4E29-4974-91D7-F79B881B2BB0

P304

Q53787362-EE6F0DF9-F756-4E8E-B2A9-B771818878BE

P31

Q53787362-C5114639-D16B-43EE-A330-92DF986AA741

P356

Q53787362-B54723F5-88D7-45DC-B00C-DFEB8DA38913

P433

Q53787362-6C459E47-D40C-4F42-A794-E8D11AE09290

P478

Q53787362-BC78AC57-C859-48D0-8DF2-6F82657541DB

P50

Q53787362-020273A0-9B7F-42FD-9A7C-DF2628DE7017

P577

Q53787362-426D90F8-958E-4176-B6C6-587E7B029BA8

P698

Q53787362-2B8E0176-B94C-4AEE-B3E1-352E74CA1790

P932

Q53787362-4ABED0C9-6EE0-4FA4-B742-BDFB06E5AFCB

P356

JAMAONCOL.2016.0494

P1433

P1476

Genomic Alterations in Cell-Fr ...... ion-Resistant Prostate Cancer.

@en

P2093

Alexander W Wyatt

http://www.w3.org/2001/XMLSchema#string

Anne Haegert

http://www.w3.org/2001/XMLSchema#string

Arun A Azad

http://www.w3.org/2001/XMLSchema#string

Brian McConeghy

http://www.w3.org/2001/XMLSchema#string

Colin C Collins

http://www.w3.org/2001/XMLSchema#string

Evan W Warner

http://www.w3.org/2001/XMLSchema#string

Fan Mo

http://www.w3.org/2001/XMLSchema#string

Kevin Beja

http://www.w3.org/2001/XMLSchema#string

Kim N Chi

http://www.w3.org/2001/XMLSchema#string

Martin E Gleave

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

Targeting the adaptive molecular landscape of castration-resistant prostate cancer

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Integrative clinical genomics of advanced prostate cancer.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer

The mutational landscape of lethal castration-resistant prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

P304

1598-1606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAONCOL.2016.0494

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27148695

http://www.w3.org/2001/XMLSchema#string

P932

5097690

http://www.w3.org/2001/XMLSchema#string